Krystal Biotech Stock Forecast
NASDAQ: KRYSHealthcareBiotechnologyUSD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
Pre-market: 327.35 +0.02%
KRYS analyst consensus
Consensus (12 analysts)
strong_buy
Avg. price target
$392.11+19.80%
- Strong buy 1
- Buy 10
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 12 Wall Street analysts covering Krystal Biotech (2026-10-09), 11 rate the stock a buy or strong buy, 1 rate it a hold and 0 rate it a sell or strong sell, for a consensus rating of "strong_buy". The average 12-month price target is $392.11, with a high estimate of $474.00 and a low estimate of $284.00. The average target implies upside of 19.8% from the current price of $327.30.
The spread between the highest and lowest targets is 66.9%, a relatively narrow range. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for KRYS.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 1 | 8% |
| Buy | 10 | 83% |
| Hold | 1 | 8% |
| Sell | 0 | 0% |
| Strong sell | 0 | 0% |
Ratings as of 2026-10-09.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $284.00 | -13.23% |
| Average target | $392.11 | +19.80% |
| High target | $474.00 | +44.82% |